Edmund Harrigan
Directeur/Membre du Conseil chez ACADIA PHARMACEUTICALS INC.
Fortune : 3 M $ au 30/04/2024
Profil
Dr. Edmund P.
Harrigan, MD, is an Independent Director at AlgoTherapeutix SAS, an Independent Director at Incyte Corp., an Independent Director at PhaseBio Pharmaceuticals, Inc. and an Independent Director at ACADIA Pharmaceuticals, Inc. He is on the Board of Directors at AlgoTherapeutix SAS, Incyte Corp., PhaseBio Pharmaceuticals, Inc. and ACADIA Pharmaceuticals, Inc. Dr. Harrigan was previously employed as an Independent Director by Bellicum Pharmaceuticals, Inc., an Independent Non-Executive Director by Karuna Therapeutics, Inc., and a SVP-Worldwide Safety & Regulatory by Pfizer Inc. He also served on the board at Lyndra Therapeutics, Inc. He received his undergraduate degree from St. Anselm College and a doctorate degree from UMass Chan Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION
0,03% | 15/04/2024 | 56 417 ( 0,03% ) | 3 M $ | 30/04/2024 |
| 29/05/2024 | 25 654 ( 0,02% ) | 418 417 $ | 30/04/2024 | |
| 19/05/2023 | 9 750 ( 0,02% ) | - $ | 31/01/2024 |
Postes actifs de Edmund Harrigan
| Sociétés | Poste | Début |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 25/11/2015 |
| PHASEBIO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 13/12/2018 |
| INCYTE CORPORATION | Directeur/Membre du Conseil | 16/12/2019 |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Directeur/Membre du Conseil | 13/04/2021 |
Anciens postes connus de Edmund Harrigan
| Sociétés | Poste | Fin |
|---|---|---|
| KARA THER | Directeur/Membre du Conseil | 03/12/2020 |
| BELLICUM PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 19/12/2019 |
| PFIZER, INC. | Conseiller Juridique Général | 01/07/2015 |
Lyndra Therapeutics, Inc.
 Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Directeur/Membre du Conseil | - |
Formation de Edmund Harrigan
| St. Anselm College | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| INCYTE CORPORATION | Health Technology |
| Entreprise privées | 4 |
|---|---|
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Technology Services |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
